Rhythm Pharmaceuticals, Inc.
Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

Abstract:

A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to .alpha.-melanocortin stimulating hormone (.alpha.-MSH).